Overactive Bladder (OAB) - Drug Pipeline Landscape, 2023
Description
Overactive Bladder (OAB) - Drug Pipeline Landscape, 2023
Overactive bladder (OAB) is a condition in which the bladder muscle contracts too often and causes urinary frequency, urgency, and incontinence. It affects both men and women, but is more common in women.
The causes of overactive bladder include neurological disorders, such as stroke, multiple sclerosis and eak pelvic muscles, diabetes, urinary tract infections, excess consumption of caffeine or alcohol, declining cognitive function due to aging, difficulty walking.
The most common symptoms of overactive bladder include urinary urgency, frequency of urination, urge incontinence and nocturia.
Healthcare provider will look for contributing factors using medical history, physical exam, urine sample to test for infection. Healthcare provider may also recommend urodynamic tests including measuring urine left in the bladder, measuring urine flow rate and testing bladder pressures.
Overactive bladder treatment include behavioral therapies, medications, bladder injections, percutaneous tibial nerve stimulation (ptns) and surgery.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Overactive Bladder treatment such as DA-8010, JLP-2002, YM178 and others. Key players involved in the development of therapies to treat Overactive Bladder are Astellas Pharma Inc, Bayer, Dong-A ST Co Ltd, Jeil Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd and others. Three drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Global Insight Service's, Overactive Bladder (OAB) - Drug Pipeline Landscape, 2023 report provides an overview of the Overactive Bladder pipeline drugs. This report covers detailed insights on Overactive Bladder (OAB) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Overactive Bladder (OAB) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Overactive bladder (OAB) is a condition in which the bladder muscle contracts too often and causes urinary frequency, urgency, and incontinence. It affects both men and women, but is more common in women.
The causes of overactive bladder include neurological disorders, such as stroke, multiple sclerosis and eak pelvic muscles, diabetes, urinary tract infections, excess consumption of caffeine or alcohol, declining cognitive function due to aging, difficulty walking.
The most common symptoms of overactive bladder include urinary urgency, frequency of urination, urge incontinence and nocturia.
Healthcare provider will look for contributing factors using medical history, physical exam, urine sample to test for infection. Healthcare provider may also recommend urodynamic tests including measuring urine left in the bladder, measuring urine flow rate and testing bladder pressures.
Overactive bladder treatment include behavioral therapies, medications, bladder injections, percutaneous tibial nerve stimulation (ptns) and surgery.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Overactive Bladder treatment such as DA-8010, JLP-2002, YM178 and others. Key players involved in the development of therapies to treat Overactive Bladder are Astellas Pharma Inc, Bayer, Dong-A ST Co Ltd, Jeil Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd and others. Three drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Global Insight Service's, Overactive Bladder (OAB) - Drug Pipeline Landscape, 2023 report provides an overview of the Overactive Bladder pipeline drugs. This report covers detailed insights on Overactive Bladder (OAB) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Overactive Bladder (OAB) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
88 Pages
- 1. Introduction
- 1.1 Overactive Bladder - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Overactive Bladder
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Overactive Bladder - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 DA-8010
- 5.1.2 JLP-2002
- 5.1.3 YM178
- 5.2 Clinical Stage Drugs-Phase II
- 5.2.1 BAY1817080
- 5.2.2 TAC-302
- 5.2.3 URO-902
- 5.3 Clinical Stage Drugs-Phase I
- 5.3.1 Botulax
- 5.3.2 DBK17001
- 5.3.3 Sunobinop
- 5.4 Early Stage Drugs- Preclinical
- 5.4.1 ARD-380
- 5.4.2 ReViVox
- 5.4.3 UI057
- 5.4.4 URB937
- 5.5 Early Stage Drugs- Discovery
- 5.5.1 PI-301
- 5.5.2 PLM-201
- 5.5.3 Urology Program
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Aardvark Therapeutics Inc
- 9.2 Astellas Pharma Inc
- 9.3 Bayer
- 9.4 DelNova
- 9.5 Dong-A ST Co., Ltd.
- 9.6 DongKoo Bio & Pharma Co Ltd
- 9.7 Exxel Pharma Inc
- 9.8 Hugel
- 9.9 Imbrium Therapeutics
- 9.10 Jeil Pharmaceutical Co., Ltd.
- 9.11 Korea United Pharm Inc
- 9.12 Pantherics Inc
- 9.13 PeLeMed Co Ltd
- 9.14 Sea4Us
- 9.15 Taiho Pharmaceutical Co., Ltd.
- 9.16 Urovant Sciences GmbH
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Overactive Bladder
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - DA-8010/Dong-A ST Co., Ltd.
- Table 2.2 Clinical Trial Details - JLP-2002/Jeil Pharmaceutical Co., Ltd.
- Table 2.3 Clinical Trial Details - BAY1817080/Bayer
- Table 2.4 Clinical Trial Details - TAC-302/Taiho Pharmaceutical Co., Ltd.
- Table 2.5 Clinical Trial Details - URO-902/Urovant Sciences GmbH
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Overactive Bladder, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Overactive Bladder, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Overactive Bladder, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Overactive Bladder, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Overactive Bladder, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
